Faecalibacteriumprausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial.

ANNÉE

2024

AUTEURS

Bredon M, le Malicot K, Louvet C, Evesque L, Gonzalez D, Tougeron D, Sokol H.

CONGRÈS/REVUE

Gastroenterology

ÉTUDE

Localisation

LIEN PUBLICATIONS ASSOCIÉES